lucinactant trade name surfaxin liquid medication used treat infant respiratory distress pulmonary surfactant infants lack enough natural surfactant lungs whereas earlier medicines class beractant survanta beraksurf calfactant infasurf poractant curosurf derived animals lucinactant synthetic approved use united states us food drug administration fda march lucinactant indicated improve lung function reduce duration risk mechanical ventilation children used two years age specified children diagnosed acute respiratory failure following exposure pathogen rsv influenza including lucinactant also used treat meconium aspiration lucinactant contains peptide sinapultide acetate kllllkllllkllllkllllk dipalmitoylphosphatidylcholine sodium salt palmitic acidcitation needed scientific groundwork lucinactant laid laboratory charles cochrane scripps research institute drug developed discovery laboratories warrington pa path approval process unusually long reflecting part challenges manufacturing process needed addressed approval lucinactant listed orphan drug product us food drug administration several clinical trials latin america criticized protocol based potentially unethical placebo used considered ethical design since infants born latin america usually access life saving treatment intent discovery labs always market surfaxin united states implying burdens latin american children outweighed benefitscitation needed httpsenwikipediaorgwikilucinactant